Search

Displaying results 1691 - 1700 of 9314 in total
  1. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

  2. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    Unlike traditional statin therapy, which relies on the upregulation of LDL receptors to clear cholesterol, Lomitapide acts independently of the LDL receptor by preventing the assembly and secretion of … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]

  3. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    binding at the ATP domain of the epidermal growth factor receptor family kinase domains. … [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed.

  4. Drug

    Cetylpyridinium

    go.drugbank.com/drugs/DB11073
    ApprovedInvestigational

    Cetylpyridinium is a quaternary ammonium with broad-spectrum antiseptic properties. Its salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, ...

    Mixtures: TANTUM VERDE GENGIVITE E STOMATITE, TANTUM VERDE GENGIVITE E STOMATITEProducts: E-zen Gargle
  5. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland. … [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]

  6. Drug

    Fluorodopa (18F)

    go.drugbank.com/drugs/DB13848
    ApprovedInvestigational

    [L12849] Fluorodopa F 18 PET is used adjunctly with other diagnostic investigations and serves primarily to visualize dopaminergic nerve terminals in the striatum.[L12849] … Fluorodopa F 18 is a fluorinated analog of [levodopa] used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes.

  7. Drug

    Clocortolone

    go.drugbank.com/drugs/DB00838
    Approved

    Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.

  8. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy … [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic

  9. Drug

    Ixekizumab

    go.drugbank.com/drugs/DB11569
    ApprovedInvestigational

    protein backbone of the molecule. … It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

  10. Drug

    Zonisamide

    go.drugbank.com/drugs/DB00909
    ApprovedInvestigational

    This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate. … [L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors